In prostate cancer, RhoC promotes tumor metastasis by sequential activation of Pyk2, focal adhesion kinase (FAK), mitogen-activated protein kinase (MAPK) and Akt, followed by the upregulation of MMP2 and MMP9, resulting in the induction of tumor cell invasion [41]. Here, WNK2 is linked to prostate carcinoma.